68 top pharmaceutical companies have changed their executive stake.

168 listed pharmaceutical companies, executive adjustmentAccording to China Net Finance, 2019 revenue of more than 100 million yuan of listed pharmaceutical companies, about 68 enterprises have adjusted the senior management level, involving China Pharmaceuticals, Fosun Pharma, Renfu Pharmaceuticals, Haizheng Pharmaceuticals, Ha Pharmaceuticals shares, China Resources Shuanghe and other well-known pharmaceutical companiesAccording to the previous Cypress Blue incomplete statistics, if not listed pharmaceutical companies and revenue as the boundary, in the first three months of 2020 alone, the pharmaceutical industry has more than 60 executives left, in April alone, 18 pharmaceutical executives offered to resign and be approved - including Haizheng Pharmaceuticals Senior Vice President Wang Haibin, Ted Pharmaceuticals President Kongtai, Renfu Pharmaceuticals Chairman Wang Xuehai, Fuxing Pharmaceuticalvice Vice President Dai Kun and so onaccording to Seiber blue combing, the reasons for the resignation of these pharmaceutical executives mainly include work reasons, personal reasons, term expiration, division of work adjustment, which mainly for personal reasons, Fosun Pharmaceuticals, Northeast Pharmaceuticals, Jiuzhitang, Dongcheng Pharmaceuticals, Jiangsu Wuzhong, Lisheng Pharmaceuticals 6 pharmaceutical companies executives left the number of 4 or more peopleof them, especially Fosun Pharma's vice president and the position of vice-president of Northeast Pharmaceuticals, the most frequent changes - according to incomplete statistics, in half a year, Fosun Pharmaceuticals' five senior executives left in succession; in addition,, across different positions, the number of senior executives who left in the first half of this year reached six - in January, Yang Lianmin and Gao Jinyan resigned as deputy general managers of Jiuzhitang at the same time;also in Wuzhong, Jiangsu Province, from March to April, In addition to Zhao Wei only to the retirement age to apply to resign as chairman, director, three other senior executives for personal reasons to resignagain not strictly to the first half of the demarcation situation, the more frequent changes in senior management of listed pharmaceutical companies have Huaren Pharmaceuticals, Ha Pharmaceutical Group, etc- according to the 2019 annual report of Ha Pharmaceuticals, as of March 31, 2020, Liu Gangmin, Wu Zhijun, Zhou Xing, Wei Shuangying 4 deputy general managers have left, including Wu Zhijun, the three reasons for leaving the job are only "personal reasons"2Multiple factors superimposed, pharmaceutical perities pressure
Beijing Dingchen Pharmaceutical Management Consulting Center founder Shi Lichen on the above phenomenon to Seibrand said that compared to the same period in previous years, this year's pharmaceutical executives change more frequentlyhe believes that the main reasons for the above phenomenon are changes in the policy environment and market environment - in the 4-7 band procurement, two-vote system, tender price reduction, medical insurance control fees and consistency evaluation of the role of the new round of national health reform policy, pharmaceutical companies are facing greater policy pressure, market competition has become more intenseUnder the pressure of policy and market, pharmaceutical companies still need performance, but many pharmaceutical executives management style and operational thinking has not yet timely adapted to the new policy and market environment, but also continue to use its original thinking and management methods, when once the performance is not completed, the frequent departure of senior executives is easy to occurShi Lichen believes that the relationship between the development of pharmaceutical companies and the decision-making level of enterprises is very close, in peacetime, senior executives can determine the development direction of pharmaceutical companies to a certain extent; However, Shi Lichen also said that it is necessary to see that the performance of pharmaceutical enterprises is not only by professional managers can be changed, some pharmaceutical companies themselves operating efficiency and management systems have serious problems, at this time, professional managers alone are difficult to improve, and even say that no matter how change managers may not be able to reverse their bad operating situation In addition to macro factors, Mr Shrichen argues that the high variability of pharmaceutical executives as professional managers has also led to frequent departures, which he says are not closee enough to pharmaceutical companies, unlike the relationship between shareholders and pharmaceutical companies Departures are easily occurring when executives are unable to meet the needs of pharmaceutical companies or when pharmaceutical companies are unable to provide the pay and career development opportunities that executives expect from the statistics can be seen that the high-frequency departure of senior executives of pharmaceutical enterprises mainly to chemical pharmaceutical enterprises, involving fewer Chinese medicine enterprises - Shi Lichen analysis pointed out that this and the first half of the chemical pharmaceutical enterprises and Chinese medicine enterprises face different developments related under the outbreak, most of the country's hospitals have been affected to varying degrees, hospital outpatient spending, inpatient volume during the outbreak decline, many chemical pharmaceutical enterprises production, logistics and distribution, marketing work is limited, production and operation affected But the outbreak has made the Chinese medicine enterprises ushered in the opportunity to glow fever, many Chinese medicine enterprises are good performance further talked about the impact of the policy of chemical pharmaceutical enterprises, the first of the import volume procurement - Shilison predicted that the impact of the volume procurement on pharmaceutical companies is continuous and high-pressure, only all chemical generics of the band procurement is done, the volume of procurement can be terminated in general, the cost of medical insurance is a normal process, the corresponding series of policies and market pressure sending personnel changes will continue It must be noted that, in addition to senior executives, frequent adjustments are also a larger volume of middle-level and grass-roots pharmaceutical company personnel, some of them actively leave their posts, some passive layoffs Source: China Net Finance.